RESEARCH TRIANGLE PARK, N.C. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 25, 2003--Tranzyme, Inc., a drug discovery and development company, and NeoGenesis Pharmaceuticals, Inc. announced today that they have expanded their collaboration to include additional genes of therapeutic interest. The collaboration will continue in the areas of gene expression and drug discovery and will utilize Tranzyme's TExT(TM) (Tranz Expression Technology) in support of the chemical genomics program at NeoGenesis. The two companies entered into their original collaboration in August 2001.
To date, Tranzyme has engineered over fifty mammalian cell lines expressing important therapeutic targets for drug discovery applications including cancer, viral diseases, CNS disorders, and metabolic diseases.
Under the expanded collaboration, NeoGenesis will provide additional sets of disease-associated gene sequences of therapeutic interest. Tranzyme will deliver these genes into different mammalian cell lines and express the proteins using its protein expression technology (TExT(TM)). NeoGenesis will deploy the purified proteins in ALIS (Automated Ligand Identification System), their ultra-high-capacity screening platform, to discover novel leads for therapeutic intervention. Further terms of the collaboration were not disclosed.
"We have been very impressed with Tranzyme's ability to express nature identical proteins in appropriate mammalian cell types," said Satish Jindal, Ph.D., President & CEO for NeoGenesis. "We expect that our continued collaboration with Tranzyme will further enhance our drug discovery capabilities."
"We are very pleased that NeoGenesis has decided to expand our current relationship," said Vipin K. Garg, Ph.D., President & CEO for Tranzyme. "This new collaboration further validates the effectiveness of Tranzyme's high-quality functional biology platform for target validation and lead identification. Since announcing our first collaboration with NeoGenesis in 2001, we have established more than a dozen industry partnerships around the world and we have been leveraging our technology in drug discovery applications."
Tranzyme, Inc. is a privately held drug discovery and development company uniquely focused on the treatment of diseases associated with the neurosensory system including the eye, the ear and the brain. Tranzyme has developed a proprietary functional biology platform based on gene delivery and controlled expression from in vitro to ex vivo to in vivo. Tranzyme is leveraging its technology through partnerships and internal programs to drive the discovery and development of novel therapeutics. The Company has already established a dozen strategic partnerships around the world and has secured access to a number of important therapeutic targets and lead compounds for neurosensory diseases. For more information about Tranzyme visit www.tranzyme.com
NeoGenesis Pharmaceuticals, Inc. is a drug discovery company focused on using its proprietary drug discovery technologies to discover and develop a portfolio of small molecule-based drugs, both for itself and for its collaboration partners. The company's universal, unbiased, affinity-based technologies, coupled with millions of diverse medicinally relevant compounds, provide an unmatched efficiency in lead discovery and optimization. NeoGenesis' core technology, the Automated Ligand Identification System (ALIS), is a rapid and universal affinity-based system for identifying and optimizing novel drug leads. Coupled with the company's NeoMorph compound library, consisting of more than 10 million diverse medicinally relevant small molecules, ALIS enables the identification of novel and selective drug leads against validated and emerging new genomic targets. Founded in 1997 and headquartered in Cambridge, Massachusetts, NeoGenesis has developed partnerships and collaborative research agreements with many of the world's leading biotechnology and pharmaceutical companies, including: Aventis Pharma, Biogen, Celltech, Japan Tobacco, Merck, Mitsubishi Pharma, Pfizer, Schering-Plough and Tularik. For more information about NeoGenesis visit www.neogenesis.com
For Tranzyme: Vipin K. Garg, Ph.D., 919-597-6614 email@example.com or
Lindsay N. Donald, DABT, 205-266-4714 firstname.lastname@example.org or
For NeoGenesis: Satish Jindal, Ph.D., 617-588-5102 email@example.com or
Steven P. Adams, Ph.D., 617-588-5108 firstname.lastname@example.org